

UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

| | |
|-------------------|------------------------------------|
| Program Number | 2019 P 3070-6 |
| Program | Step Therapy |
| Medication | Hydrocodone/guaifenesin solution |
| P&T Approval Date | 2/2016, 3/2017, 3/2018, 1/2019 |
| Effective Date | 4/1/2019; Oxford only: 4/1/2019 |

1. Background:

Hydrocodone/guaifenesin is a combination product containing an opioid antitussive and expectorant indicated for symptomatic relief of cough and to loosen mucus associated with the common cold.

Step Therapy programs are utilized to encourage use of lower cost alternatives for certain therapeutic classes.

2. Coverage Criteria^a:

A. Hydrocodone/guaifenesin solution will be approved based on the following criterion:

1. History of failure, contraindication, or intolerance to Cheratussin AC (codeine/guaifenesin [generic Robitussin AC]).

Authorization will be issued for 12 months.

^a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place.

4. References:

1. Hydrocodone bitartrate and guaifenesin solution prescribing information. Burke Therapeutics. Hot Springs, AR. April 2018.

| | |
|-----------------------|--|
| Program | Step Therapy – Hydrocodone/guaifenesin |
| Change Control | |
| Date | Change |
| 2/2016 | New program |
| 7/2016 | Added Indiana and West Virginia coverage information. |
| 11/2016 | Administrative change. Added California coverage information. |
| 3/2017 | Annual review. State mandate reference language updated. |
| 3/2018 | Annual review. Updated references. |
| 1/2019 | Removed Obredon as it is off the market. Added hydrocodone/guaifenesin solution. |